Vyne Therapeutics Stock Performance
| VYNE Stock | USD 2.95 0.08 2.64% |
On a scale of 0 to 100, Vyne Therapeutics holds a performance score of 15. The entity has a beta of -0.26, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Vyne Therapeutics are expected to decrease at a much lower rate. During the bear market, Vyne Therapeutics is likely to outperform the market. Please check Vyne Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Vyne Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
15 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Vyne Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Vyne Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.18) | Five Day Return 10.48 | Year To Date Return 31.32 | Ten Year Return (99.86) | All Time Return (99.86) |
Last Split Factor 1:18 | Last Split Date 2023-02-13 |
1 | Tarabut Acquires UK Payments Platform Vyne Ahead of New MENA Regulatory Requirements | 09/03/2024 |
2 | VYNE Therapeutics Inc. Reports Q2 Loss, Tops Revenue Estimates - MSN | 09/24/2024 |
3 | Disposition of 105 shares by Harsch Mutya of Vyne Therapeutics at 1.88 subject to Rule 16b-3 | 09/30/2024 |
4 | Were Keeping An Eye On VYNE Therapeutics Cash Burn Rate | 10/09/2024 |
5 | Disposition of 1154 shares by Harsch Mutya of Vyne Therapeutics at 3.83 subject to Rule 16b-3 | 10/18/2024 |
6 | Acquisition by David Domzalski of 4429 shares of Vyne Therapeutics at 2.159 subject to Rule 16b-3 | 11/01/2024 |
7 | BioCryst Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates | 11/04/2024 |
8 | VYNE Therapeutics GAAP EPS of -0.29, revenue of 0.1M | 11/07/2024 |
9 | VYNE Therapeutics Inc. Reports Q3 Loss, Tops Revenue Estimates - MSN | 11/20/2024 |
| Begin Period Cash Flow | 31 M |
Vyne |
Vyne Therapeutics Relative Risk vs. Return Landscape
If you would invest 180.00 in Vyne Therapeutics on August 28, 2024 and sell it today you would earn a total of 115.00 from holding Vyne Therapeutics or generate 63.89% return on investment over 90 days. Vyne Therapeutics is currently generating 0.882% in daily expected returns and assumes 4.4459% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Vyne, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vyne Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vyne Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vyne Therapeutics, and traders can use it to determine the average amount a Vyne Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1984
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VYNE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.45 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.88 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Vyne Therapeutics is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vyne Therapeutics by adding it to a well-diversified portfolio.
Vyne Therapeutics Fundamentals Growth
Vyne Stock prices reflect investors' perceptions of the future prospects and financial health of Vyne Therapeutics, and Vyne Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vyne Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (52.51) % | ||||
| Current Valuation | (25.37 M) | ||||
| Shares Outstanding | 14.75 M | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 90.66 X | ||||
| Revenue | 424 K | ||||
| Gross Profit | 477 K | ||||
| EBITDA | (29.26 M) | ||||
| Net Income | (28.45 M) | ||||
| Cash And Equivalents | 42.81 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 214 K | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 6.29 X | ||||
| Cash Flow From Operations | (25.34 M) | ||||
| Earnings Per Share | 1.72 X | ||||
| Market Capitalization | 44.25 M | ||||
| Total Asset | 97.69 M | ||||
| Retained Earnings | (691.34 M) | ||||
| Working Capital | 88.42 M | ||||
About Vyne Therapeutics Performance
By analyzing Vyne Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Vyne Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vyne Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vyne Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 914.10 | 1,522 | |
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.32) | (0.34) |
Things to note about Vyne Therapeutics performance evaluation
Checking the ongoing alerts about Vyne Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vyne Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vyne Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 424 K. Net Loss for the year was (28.45 M) with profit before overhead, payroll, taxes, and interest of 477 K. | |
| Vyne Therapeutics currently holds about 42.81 M in cash with (25.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Vyne Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: VYNE Therapeutics Inc. Reports Q3 Loss, Tops Revenue Estimates - MSN |
- Analyzing Vyne Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vyne Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Vyne Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vyne Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vyne Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vyne Therapeutics' stock. These opinions can provide insight into Vyne Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vyne Stock analysis
When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |